ATPases as drug targets: Insights from heat shock proteins 70 and 90

Journal of Medicinal Chemistry

Volumn 53, Issue 20, 2010, Pages 7280-7286

  Massey, Andrew J ^a  

^a Vernalis PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE INHIBITOR; ANTINEOPLASTIC AGENT; BEP NVP 800; BIIB 021; BIIB 0221; DMT 003052; GALACTOLIPID; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IPI 493; NVP BEP 800; PHENYLETHYNESULFONAMIDE; RADICICOL; SNX 5422; STA 9090; SULFONAMIDE; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; VER 155008; XL 888; ADENOSINE TRIPHOSPHATE; PROTEIN BINDING;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LIVER TOXICITY; NEOPLASM; NONHUMAN; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 77958516062     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100342z     Document Type: Review

References (59)

1. Chene, P. ATPases as drug targets: learning from their structure Nat. Rev. Drug Discovery 2002, 1 (9) 665-673
2. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer Nat. Rev. Cancer 2005, 5 (10) 761-772
3. Mimnaugh, E. G.; Xu, W.; Vos, M.; Yuan, X.; Isaacs, J. S.; Bisht, K. S.; Gius, D.; Neckers, L. Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity Mol. Cancer Ther. 2004, 3 (5) 551-566
4. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic expolitation on oncogene addiction and tumor stress Ann. N.Y. Acad. Sci. 2007, 1113 (Stress Responses in Biology and Medicine) 202-216
5. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G. Targeting Hsp90: small-molecule inhibitors and their clinical development Curr. Opin. Pharmacol. 2008, 8 (4) 370-374
6. Solit, D. B.; Ivy, S. P.; Kopil, C.; Sikorski, R.; Morris, M. J.; Slovin, S. F.; Kelly, W. K.; DeLaCruz, A.; Curley, T.; Heller, G.; Larson, S.; Schwartz, L.; Egorin, M. J.; Rosen, N.; Scher, H. I. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer Clin. Cancer Res. 2007, 13 (6) 1775-1782 (Pubitemid 46952945)
7. Gaspar, N.; Sharp, S. Y.; Pacey, S.; Jones, D.; Walton, M.; Vassal, G.; Eccles, S.; Pearson, A.; Workman, P. Acquired resistance to 17-allylamino-17- demethoxygeldanamycin (tanespimycin) in glioblastoma cells Cancer Res. 2009, 69 (5) 1966-1975
8. Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, K. M.; Collins, I.; Davies, N. G.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J. Med. Chem. 2008, 51 (2) 196-218
9. Eccles, S. A.; Massey, A.; Raynaud, F. I.; Sharp, S. Y.; Box, G.; Valenti, M.; Patterson, L.; de Haven, B. A.; Gowan, S.; Boxall, F.; Aherne, W.; Rowlands, M.; Hayes, A.; Martins, V.; Urban, F.; Boxall, K.; Prodromou, C.; Pearl, L.; James, K.; Matthews, T. P.; Cheung, K. M.; Kalusa, A.; Jones, K.; McDonald, E.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Dymock, B.; Drysdale, M. J.; Finch, H.; Howes, R.; Hubbard, R. E.; Surgenor, A.; Webb, P.; Wood, M.; Wright, L.; Workman, P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis Cancer Res. 2008, 68 (8) 2850-2860
10. Jensen, M. R.; Schoepfer, J.; Radimerski, T.; Massey, A.; Guy, C. T.; Brueggen, J.; Quadt, C.; Buckler, A.; Cozens, R.; Drysdale, M. J.; Garcia-Echeverria, C.; Chene, P. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models Breast Cancer Res. 2008, 10 (2) R33
11. Lundgren, K.; Zhang, H.; Brekken, J.; Huser, N.; Powell, R. E.; Timple, N.; Busch, D. J.; Neely, L.; Sensintaffar, J. L.; Yang, Y. C.; McKenzie, A.; Friedman, J.; Scannevin, R.; Kamal, A.; Hong, K.; Kasibhatla, S. R.; Boehm, M. F.; Burrows, F. J. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 Mol. Cancer Ther. 2009, 8 (4) 921-929
12. Biamonte, M. A.; Van de, W. R.; Arndt, J. W.; Scannevin, R. H.; Perret, D.; Lee, W. C. Heat shock protein 90: inhibitors in clinical trials J. Med. Chem. 2010, 53 (1) 3-17
13. Drysdale, M. J.; Brough, P. A.; Massey, A.; Jensen, M. R.; Schoepfer, J. Targeting Hsp90 for the treatment of cancer Curr. Opin. Drug Discovery Dev. 2006, 9 (4) 483-495
14. Taldone, T.; Sun, W.; Chiosis, G. Discovery and development of heat shock protein 90 inhibitors Bioorg. Med. Chem. 2009, 17 (6) 2225-2235
15. Kim, Y. S.; Alarcon, S. V.; Lee, S.; Lee, M. J.; Giaccone, G.; Neckers, L.; Trepel, J. B. Update on Hsp90 inhibitors in clinical trial Curr. Top. Med. Chem. 2009, 9 (15) 1479-1492
16. Mayer, M. P.; Bukau, B. Hsp70 chaperones: cellular functions and molecular mechanism Cell. Mol. Life Sci. 2005, 62 (6) 670-684
17. Young, J. C.; Agashe, V. R.; Siegers, K.; Hartl, F. U. Pathways of chaperone-mediated protein folding in the cytosol Nat. Rev. Mol. Cell Biol. 2004, 5 (10) 781-791
18. Young, J. C.; Barral, J. M.; Ulrich, H. F. More than folding: localized functions of cytosolic chaperones Trends Biochem. Sci. 2003, 28 (10) 541-547
19. Nylandsted, J.; Brand, K.; Jaattela, M. Heat shock protein 70 is required for the survival of cancer cells Ann. N.Y. Acad. Sci. 2000, 926, 122-125
20. Nylandsted, J.; Wick, W.; Hirt, U. A.; Brand, K.; Rohde, M.; Leist, M.; Weller, M.; Jaattela, M. Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion Cancer Res. 2002, 62 (24) 7139-7142
21. Schmitt, E.; Maingret, L.; Puig, P. E.; Rerole, A. L.; Ghiringhelli, F.; Hammann, A.; Solary, E.; Kroemer, G.; Garrido, C. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma Cancer Res. 2006, 66 (8) 4191-4197
22. Guo, F.; Rocha, K.; Bali, P.; Pranpat, M.; Fiskus, W.; Boyapalle, S.; Kumaraswamy, S.; Balasis, M.; Greedy, B.; Armitage, E. S.; Lawrence, N.; Bhalla, K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin Cancer Res. 2005, 65 (22) 10536-10544
23. Gabai, V. L.; Budagova, K. R.; Sherman, M. Y. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents Oncogene 2005, 24 (20) 3328-3338
24. Zaarur, N.; Gabai, V. L.; Porco, J. A., Jr.; Calderwood, S.; Sherman, M. Y. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors Cancer Res. 2006, 66 (3) 1783-1791
25. Powers, M. V.; Clarke, P. A.; Workman, P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis Cancer Cell 2008, 14 (3) 250-262
26. Evans, C. G.; Chang, L.; Gestwicki, J. E. Heat shock protein 70 (Hsp70) as an emerging drug target J. Med. Chem. 2010, 53 (12) 4585-4602
27. Powers, M. V.; Jones, K.; Barillari, C.; Westwood, I.; van Montfort, R. L.; Workman, P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 2010, 9 (8) 1542-1550
28. Williamson, D. S.; Borgognoni, J.; Clay, A.; Daniels, Z.; Dokurno, P.; Drysdale, M. J.; Foloppe, N.; Francis, G. L.; Graham, C. J.; Howes, R.; Macias, A. T.; Murray, J. B.; Parsons, R.; Shaw, T.; Surgenor, A. E.; Terry, L.; Wang, Y.; Wood, M.; Massey, A. J. Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design J. Med. Chem. 2009, 52 (6) 1510-1513
29. Massey, A. J.; Williamson, D. S.; Browne, H.; Murray, J. B.; Dokurno, P.; Shaw, T.; Macias, A. T.; Daniels, Z.; Geoffroy, S.; Dopson, M.; Lavan, P.; Matassova, N.; Francis, G. L.; Graham, C. J.; Parsons, R.; Wang, Y.; Padfield, A.; Comer, M.; Drysdale, M. J.; Wood, M. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells Cancer Chemother. Pharmacol. 2010, 66, 535-545
30. Leu, J. I.; Pimkina, J.; Frank, A.; Murphy, M. E.; George, D. L. A small molecule inhibitor of inducible heat shock protein 70 Mol. Cell 2009, 36 (1) 15-27
31. Patury, S.; Miyata, Y.; Gestwicki, J. E. Pharmacological targeting of the Hsp70 chaperone Curr. Top. Med. Chem. 2009, 9 (15) 1337-1351
32. Fewell, S. W.; Smith, C. M.; Lyon, M. A.; Dumitrescu, T. P.; Wipf, P.; Day, B. W.; Brodsky, J. L. Small molecule modulators of endogenous and co-chaperone-stimulated Hsp70 ATPase activity J. Biol. Chem. 2004, 279 (49) 51131-51140
33. Fewell, S. W.; Day, B. W.; Brodsky, J. L. Identification of an inhibitor of hsc70-mediated protein translocation and ATP hydrolysis J. Biol. Chem. 2001, 276 (2) 910-914
34. Wisen, S.; Gestwicki, J. E. Identification of small molecules that modify the protein folding activity of heat shock protein 70 Anal. Biochem. 2008, 374 (2) 371-377
35. Mamelak, D.; Lingwood, C. The ATPase domain of hsp70 possesses a unique binding specificity for 3′-sulfogalactolipids J. Biol. Chem. 2001, 276 (1) 449-456
36. Whetstone, H.; Lingwood, C. 3′-Sulfogalactolipid binding specifically inhibits Hsp70 ATPase activity in vitro Biochemistry 2003, 42 (6) 1611-1617
37. SiteMap, version 2.2; Schrodinger LLC (120 West 45th Street, New York, NY 10036), 2008.
38. Halgren, T. A. Identifying and characterizing binding sites and assessing druggability J. Chem. Inf. Model. 2009, 49, 377-389
39. Chen, I. J.; Hubbard, R. E. Lessons for fragment library design: analysis of output from multiple screening campaigns J. Comput.-Aided Mol. Des. 2009, 23, 603-620
40. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 2005, 48 (7) 2518-2525
41. Hubbard, R. E.; Davis, B.; Chen, I.; Drysdale, M. J. The SeeDs approach: integrating fragments into drug discovery Curr. Top. Med. Chem. 2007, 7 (16) 1568-1581
42. Potter, A. J.; Ray, S.; Gueritz, L.; Nunns, C. L.; Bryant, C. J.; Scrace, S. F.; Matassova, N.; Baker, L.; Dokurno, P.; Robinson, D. A.; Surgenor, A. E.; Davis, B.; Murray, J. B.; Richardson, C. M.; Moore, J. D. Structure-guided design of alpha-amino acid-derived Pin1 inhibitors Bioorg. Med. Chem. Lett. 2010, 20 (2) 586-590
43. Shida, M.; Arakawa, A.; Ishii, R.; Kishishita, S.; Takagi, T.; Kukimoto-Niino, M.; Sugano, S.; Tanaka, A.; Shirouzu, M.; Yokoyama, S. Direct inter-subdomain interactions switch between the closed and open forms of the Hsp70 nucleotide-binding domain in the nucleotide-free state Acta Crystallogr., Sect. D.: Biol. Crystallogr. 2010, 66 (Part 3) 223-232
44. Weikl, T.; Muschler, P.; Richter, K.; Veit, T.; Reinstein, J.; Buchner, J. C-terminal regions of Hsp90 are important for trapping the nucleotide during the ATPase cycle J. Mol. Biol. 2000, 303 (4) 583-592
45. Ha, J. H.; McKay, D. B. ATPase kinetics of recombinant bovine 70 kDa heat shock cognate protein and its amino-terminal ATPase domain Biochemistry 1994, 33 (48) 14625-14635
46. Borges, J. C.; Ramos, C. H. Spectroscopic and thermodynamic measurements of nucleotide-induced changes in the human 70-kDa heat shock cognate protein Arch. Biochem. Biophys. 2006, 452 (1) 46-54
47. Sriram, M.; Osipiuk, J.; Freeman, B.; Morimoto, R.; Joachimiak, A. Human Hsp70 molecular chaperone binds two calcium ions within the ATPase domain Structure 1997, 5 (3) 403-414
48. Sondermann, H.; Scheufler, C.; Schneider, C.; Hohfeld, J.; Hartl, F. U.; Moarefi, I. Structure of a Bag/Hsc70 complex: convergent functional evolution of Hsp70 nucleotide exchange factors Science 2001, 291 (5508) 1553-1557
49. Fersht, A. R. The hydrogen bond in molecular recognition Trends Biochem. Sci. 1987, 12, 301-304
50. Prodromou, C.; Roe, S. M.; OBrien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone Cell 1997, 90 (1) 65-75
51. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent Cell 1997, 89 (2) 239-250
52. Meyer, P.; Prodromou, C.; Hu, B.; Vaughan, C.; Roe, S. M.; Panaretou, B.; Piper, P. W.; Pearl, L. H. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions Mol. Cell 2003, 11 (3) 647-658
53. Ali, M. M.; Roe, S. M.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Crystal structure of an Hsp90-nucleotide-p23/ Sba1 closed chaperone complex Nature 2006, 440 (7087) 1013-1017
54. Brough, P. A.; Barril, X.; Borgognoni, J.; Chene, P.; Davies, N. G.; Davis, B.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Garcia-Echeverria, C.; Fromont, C.; Hayes, A.; Hubbard, R. E.; Jordan, A. M.; Jensen, M. R.; Massey, A.; Merrett, A.; Padfield, A.; Parsons, R.; Radimerski, T.; Raynaud, F. I.; Robertson, A.; Roughley, S. D.; Schoepfer, J.; Simmonite, H.; Sharp, S. Y.; Surgenor, A.; Valenti, M.; Walls, S.; Webb, P.; Wood, M.; Workman, P.; Wright, L. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3- d ]pyrimidine inhibitors of the Hsp90 molecular chaperone J. Med. Chem. 2009, 52 (15) 4794-4809
55. Massey, A. J.; Schoepfer, J.; Brough, P. A.; Brueggen, J.; Chene, P.; Drysdale, M. J.; Pfaar, U.; Radimerski, T.; Ruetz, S.; Schweitzer, A.; Wood, M.; Garcia-Echeverria, C.; Jensen, M. R. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800 Mol. Cancer Ther. 2010, 9 (4) 906-919
56. Sharp, A.; Cutress, R. I.; Johnson, P. W.; Packham, G.; Townsend, P. A. Short peptides derived from the BAG-1 C-terminus inhibit the interaction between BAG-1 and HSC70 and decrease breast cancer cell growth FEBS Lett. 2009, 583 (21) 3405-3411
57. Powers, M. V.; Clarke, P. A.; Workman, P. Death by chaperone: HSP90, HSP70 or both? Cell Cycle 2009, 8 (4) 518-526
58. de Billy, E.; Powers, M. V.; Smith, J. R.; Workman, P. Drugging the heat shock factor 1 pathway: exploitation of the critical cancer cell dependence on the guardian of the proteome Cell Cycle 2009, 8 (23) 3806-3808
59. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors Chem. Biol. 2005, 12 (6) 621-637